No abstract

Aiming at improving the enterprise performance and venture capital management, the edge computing is combined with blockchain technology in the construction of the supply chains so as to improve the stability and security of raw material supply chains of venture capital enterprises. Firstly, the relationships among venture capital, enterprise performance, and supply chain integration are analyzed, and the positive impacts of optimization and innovation of supply chain technology and venture capital on enterprise performance improvement are discussed. Secondly, the edge computing and blockchain technology are adopted to optimize the supply chain, and a protocol model is established to improve the security of supply chain information transmission. In addition, the supply chain Internet of Things (IoT) system is designed in layers based on blockchain and edge computing technology. Finally, the designed protocol model is applied to the supply chain and the supplier performance is evaluated by using the fuzzy analytic hierarchy process (FAHP). The results show that the gas value of the designed protocol model is stable at 104,000∼116,000 in blockchain transactions, and the execution time of a single blockchain transaction fluctuates between 4,300 and 6,100 ms. Therefore, the designed protocol model can effectively ensure the security of supply chain data during the transmission. The evaluation results of supplier performance suggest that the cooperative relationship between venture capital enterprises and suppliers is affected by many factors. Optimizing the supply chain structure and production activities can improve the performance of suppliers and venture capital enterprises. This work provides a reference for analyzing the performance of blockchain technology on venture capital enterprises and suppliers.

Clinical and translational medicine is an ongoing opportunity and challenge to transition science from bench to patient, from patient to bench, and from patient to policy for scientists and clinicians. Of the many objectives, the most important one is to improve the quality of life in patients, including living duration, dignity, emotional well‐being, psychiatric and physical health, as well as independency. Emphasis and redefining concepts has allowed clinical and translational medicine to experience exciting and productive developments. Further discoveries, innovations, validations, and developments in clinical and translational medicine are expected in 2020. The present editorial aims to present the top three most discussed topics with high expectations for translation from clinical investigations and trials into practice and application.

No abstract